Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 1 Sell Rating(s), 10 Hold Rating(s), 11 Buy Rating(s)
Consensus Rating:Hold (Score: 2.45)
Consensus Price Target: $37.62 (147.63% upside)

Current Analysts' Coverage Summary for Sarepta Therapeutics (NASDAQ:SRPT)
Show:
DateFirmActionRatingPrice TargetDetailsShare
10/28/2014Robert W. BairdDowngradeOutperform -> Neutral$53.00 -> $21.00ViewTweet This Rating  Share This Rating on StockTwits
10/27/2014Stifel NicolausDowngradeBuy -> HoldViewTweet This Rating  Share This Rating on StockTwits
10/27/2014JMP SecuritiesDowngradeOutperform -> Market PerformViewTweet This Rating  Share This Rating on StockTwits
10/13/2014ZacksReiterated RatingNeutral -> Neutral$20.00ViewTweet This Rating  Share This Rating on StockTwits
10/7/2014Credit SuisseReiterated RatingOutperformViewTweet This Rating  Share This Rating on StockTwits
8/19/2014Cowen and CompanyInitiated CoverageOutperform$44.00ViewTweet This Rating  Share This Rating on StockTwits
7/31/2014OppenheimerInitiated CoverageOutperform$45.00ViewTweet This Rating  Share This Rating on StockTwits
7/30/2014Deutsche BankReiterated RatingPositiveViewTweet This Rating  Share This Rating on StockTwits
7/29/2014WBB SecuritiesUpgradeSpeculative Buy -> BuyViewTweet This Rating  Share This Rating on StockTwits
7/22/2014Bank of AmericaInitiated CoverageNeutral$27.00ViewTweet This Rating  Share This Rating on StockTwits
5/22/2014Roth CapitalInitiated CoverageBuy$52.00ViewTweet This Rating  Share This Rating on StockTwits
4/22/2014Citigroup Inc.UpgradeSell -> NeutralViewTweet This Rating  Share This Rating on StockTwits
4/21/2014Canaccord GenuityUpgradeHold -> Buy$27.00 -> $63.00ViewTweet This Rating  Share This Rating on StockTwits
4/21/2014Needham & Company LLCReiterated RatingBuy$36.00 -> $52.00ViewTweet This Rating  Share This Rating on StockTwits
4/21/2014William BlairUpgradeMarket Perform -> Outperform$63.00ViewTweet This Rating  Share This Rating on StockTwits
4/14/2014SidotiInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
12/23/2013Piper JaffrayUpgradeUnderweight -> Neutral$19.55 -> $20.00ViewTweet This Rating  Share This Rating on StockTwits
11/12/2013Leerink SwannLower Price TargetMarket Perform$44.00 -> $17.00ViewTweet This Rating  Share This Rating on StockTwits
11/12/2013WedbushLower Price TargetOutperform$60.00 -> $45.00ViewTweet This Rating  Share This Rating on StockTwits
11/12/2013FBR Capital MarketsLower Price TargetMarket Perform$48.00 -> $20.00ViewTweet This Rating  Share This Rating on StockTwits
11/12/2013Janney Montgomery ScottDowngradeNeutral -> SellViewTweet This Rating  Share This Rating on StockTwits
10/30/2013FBR & CoInitiated CoverageMarket PerformViewTweet This Rating  Share This Rating on StockTwits
7/24/2013Burrill Institutional ResearchDowngradeOutperform -> Market Perform$39.00ViewTweet This Rating  Share This Rating on StockTwits
11/27/2012Dominick & DominickInitiated CoverageMarket PerformViewTweet This Rating  Share This Rating on StockTwits
11/27/2012Dawson JamesInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
(Data available from 10/30/2012 forward)
Discuss Sarepta Therapeutics